Corrigendum

This article refers to:

Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies

Article title: “Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies”

Authors: Rajul K Jain, David S Hong, Aung Naing, Jennifer Wheler, Thorunn Helgason, Nai-Yi Shi, Yash Gad, and Razelle Kurzrock

Journal: Cell Cycle

Bibliometrics: Volume 14, Issue 21, pages 3434–3440

DOI: 10.1080/15384101.2015.1090065

Incorrect data was presented in the Abstract in the online and print versions.

The maximum tolerated dose for bortezomib should be 0.6 mg/m2 IV D1, 4, 8, 11 rather than 0.9 mg/m2 IV D1, 4, 8, 11.

The authors apologize for any inconvenience.